SKYE

SKYEPHARMA PLC ADS

SKYE

Overview Fund Activity

Delisted

SKYE was delisted on the 11th of May, 2007.

Back to rankings

Financial journalist opinion

Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that the last patient has completed 26 weeks of treatment in the main study of its Phase 2a CBeyond™ clinical trial evaluating nimacimab, Skye's peripherally-restricted CB1 inhibitor antibody, for the treatment of obesity and overweight.

Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout

Virtual KOL event will begin at 8:00 AM ET on Thursday, September 4, 2025 Virtual KOL event will begin at 8:00 AM ET on Thursday, September 4, 2025

Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it will participate in the following upcoming investment and medical conferences:

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript

Skye Bioscience, Inc. (NASDAQ:SKYE ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Kaitlyn Melanie Arsenault - Chief Financial Officer Puneet S. Arora - Chief Medical Officer Punit S.

Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript

The Motley Fool

Skye (SKYE) Q2 R&D Soars 249% No Revenue

Skye Bioscience (SKYE -8.23%), a biotechnology company developing novel obesity therapeutics, released its second quarter earnings on August 7, 2025. As in prior quarters, no commercial revenue was reported.

Skye (SKYE) Q2 R&D Soars 249% No Revenue

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the second quarter ended June 30, 2025, along with key accomplishments and upcoming milestones.

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

SAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Thursday, August 7, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss its second quarter 2025 financial results. The Company will issue its financial results and business update press release after the market closes on the same day.

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing

Skye Bioscience's Nimacimab remains a promising peripheral CB1 antibody for obesity with lean-mass preservation and fewer GI issues. Nimacimab's Phase 2a topline is expected by Q3-Q4 2025, which is its next catalyst in the short term. Since Nimacimab can also help with GLP-1 non-responders or as a maintenance therapy, it shows an added potential as a combo therapy.

Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions

SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced the debut of its “Anatomy of Progress” nimacimab development update video series and availability of presentations related to the development of its anti-obesity drug, nimacimab, presented in multiple forums at the American Diabetes Association's (ADA) 85th Scientific Sessions held June 20-23, 2025, in Chicago, Illinois. The presentations are accessible at the following link.

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions

SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it was selected to present new nimacimab data in its expanded preclinical model at the upcoming American Diabetes Association's (ADA) 85th Scientific Sessions. Skye will present in multiple forums at the ADA conference, which is being held June 20th – 23rd, 2025, at the McCormick Place Convention Center in Chicago, Illinois.

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions

See News Rankings

Charts implemented using Lightweight Charts™